Tianjin Development (00882.HK) plans to invest 174 million yuan through its subsidiary to participate in establishing a fund.

Zhixin Finance APP News, Tianjin Development (00882.HK) announced that Lifespring Pharmaceutical (an indirectly non-wholly-owned subsidiary of the company) intends to enter into a partnership agreement with Jianxin Equity (as the fund's manager and general partner), Taida Private Equity (as the fund's general partner), GQ Constructionxing (as a special limited partner), Taida International, state-owned mother funds, and Zhanxin Fund (each as limited partners) to establish a fund. The proposed total amount of subscribed capital for the fund is 500 million yuan, of which Lifespring Pharmaceutical (as a limited partner) intends to subscribe 174 million yuan to the fund, accounting for 34.75% of the proposed total subscribed capital of the fund, subject to the terms and conditions of the partnership agreement.